DURHAM, N.C., Feb. 22, 2018 -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that it will host a live conference call and audio webcast on Thursday, March 1, 2018 at 8:30 a.m. ET to report financial results for the fourth quarter and full year ended December 31, 2017, and to provide a business overview.
To access the live conference call, please dial (877) 354-4056 (domestic) or (678) 809-1043 (international) at least five minutes prior to the start time, and refer to conference ID 1153769. A live audio webcast of the call will also be available on the Investors’ section of the Company's website, www.chimerix.com. An archived webcast will be available on the Chimerix website approximately two hours after the event.
About Chimerix
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology and Compound Library have produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and a new clinical candidate, CMX521, the first direct-acting antiviral specifically for the treatment and prevention of norovirus to enter clinical testing. For further information, please visit Chimerix's website, www.chimerix.com.
CONTACT:
Investor Relations:
Michelle LaSpaluto
919-972-7115
[email protected]
or
Will O’Connor
Stern Investor Relations
[email protected]
212-362-1200
Media:
Becky Vonsiatsky
W2O Group
[email protected]
413-478-2003


Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 



